Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when AIDX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alerts20/20 Biolabs reports Q1 2026 financial results
Filed May 20, 2026 · Period ending May 20, 2026 · ~1 min read
Key Changes
-
medium
Company disclosed first quarter 2026 financial results for the period ended March 31, 2026, via press release. Specific financial figures are contained in the attached exhibit rather than the filing body.
Item 2.02 verify on EDGAR →
Summary
20/20 Biolabs filed an 8-K to announce its first quarter 2026 financial results. This is a routine earnings disclosure, with the actual financial data provided in an attached press release rather than in the body of the SEC filing itself. For retail investors, this represents a standard quarterly reporting event.
The filing confirms the company is maintaining its disclosure obligations but provides limited detail without reviewing the press release exhibit. Investors should review the full press release for revenue, earnings, cash position, and any forward guidance the company provided. Watch for any commentary on product development milestones or changes in the company's cash runway, which are typically critical metrics for early-stage biotech firms.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 20, 2026, 20/20 Biolabs, Inc. (the “Company”) issued a press release regarding its financial results for the quarter ended March 31, 2026.
The company announced its first quarter 2026 financial results through a press release. The 8-K filing itself does not contain the actual financial figures, which are provided in the attached press release exhibit. This is a standard earnings disclosure event.
Event · Item 9.01 — Financial Statements and Exhibits
20/20 Biolabs filed an 8-K attaching a press release issued May 20, 2026; no material event details disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press Release issued on May 20, 2026
The 8-K references a press release dated May 20, 2026, but the filing body does not disclose the content or subject matter of that release. Without the exhibit text, the materiality and investor impact cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 25, 2026 · How we verify